Immune modulation with IL-2 and IL-12. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immune modulation with IL-2 and IL-12. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

STEP Perspect. 1997 Winter;9(1):9-12. Unique Identifier : AIDSLINE AIDS/97702557
Boonprakong L; University of Washington, School of Medicine, AIDS Clinical; Trials Unit, Seattle, WA.

Abstract: Scientists have identified a number of chemical messengers that play a fundamental role in directing the body's natural response to the invasion of organisms and pathogens in the human immune system. One group, cytokines, are an essential communications link between the cells of the immune system and the body. The decrease in immune function with HIV is apparent in both the amount of HIV detected and in the decline in CD4 cells. Levels of two cytokines, IL-12 and IL-2, appear to have a direct correlation to cellular immunity. Treatment with these two substances may strengthen immune function and decrease the pace of disease development. Recombinant forms have been developed as hopeful treatments for cancer, HIV, and other infectious diseases.
Keywords: Anti-HIV Agents/THERAPEUTIC USE CD4-Positive T-Lymphocytes/*IMMUNOLOGY Cytokines/IMMUNOLOGY/THERAPEUTIC USE Didanosine/THERAPEUTIC USE Drug Therapy, Combination HIV Infections/*DRUG THERAPY/*IMMUNOLOGY Human Interleukin-12/*IMMUNOLOGY/*THERAPEUTIC USE Interleukin-2/*IMMUNOLOGY/*THERAPEUTIC USE Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLEKWDanti-hivagents/therapeuticusecd4-positivet-lymphocytes/KWDimmunologycytokines/immunology/therapeuticusedidanosine/therapeuticusedrugtherapy,combinationhivinfections/KWDdrugtherapy/KWDimmunologyhumaninterleukin-12/KWDimmunology/KWDtherapeuticuseinterleukin-2/KWDimmunology/KWDtherapeuticusezidovudine/therapeuticusenewsletterarticle
970830
M9781194

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .